July 10, 2024

Uncategorized

New Releases from NCBI BookshelfAvatrombopag (Doptelet): CADTH Reimbursement Recommendation: Indication: For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment [Internet].​Avatrombopag (Doptelet): CADTH Reimbursement Recommendation: Indication: For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment [Internet].

We recommend that Doptelet not be reimbursed by public drug plans for the treatment of thrombocytopenia in adults with chronic […]

Uncategorized

New Releases from NCBI BookshelfAnticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy: Rapid Review [Internet].​Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy: Rapid Review [Internet].

Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the most common toxicities secondary to T-cell engager

Uncategorized

New Releases from NCBI BookshelfAlemtuzumab, Cladribine, Fingolimod, Natalizumab, and Rituximab as First-Line Treatments in Adults With Highly Active Relapsing-Remitting Multiple Sclerosis: Health Technology Assessment [Internet].​Alemtuzumab, Cladribine, Fingolimod, Natalizumab, and Rituximab as First-Line Treatments in Adults With Highly Active Relapsing-Remitting Multiple Sclerosis: Health Technology Assessment [Internet].

Relapsing-remitting multiple sclerosis (RRMS), the most common disease course of multiple sclerosis (MS), is a chronic immune-mediated disease with clearly

Scroll to Top